Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Sadick Research Group
mi
from
New York, NY
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Sadick Research Group
mi
from
New York, NY
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Vital Prospects Clinical Research Institute, P.C.
mi
from
Tulsa, OK
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Vital Prospects Clinical Research Institute, P.C.
mi
from
Tulsa, OK
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
DermDox Centers for Dermatology
mi
from
Hazleton, PA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
DermDox Centers for Dermatology
mi
from
Hazleton, PA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Clinical Partners, LLC
mi
from
Johnston, RI
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Clinical Partners, LLC
mi
from
Johnston, RI
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Health Concepts
mi
from
Rapid City, SD
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Health Concepts
mi
from
Rapid City, SD
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Bellaire Dermatology Associates
mi
from
Bellaire, TX
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Bellaire Dermatology Associates
mi
from
Bellaire, TX
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Texas Dermatology and Laser Specialists
mi
from
San Antonio, TX
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Texas Dermatology and Laser Specialists
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
West End Dermatology Associates
mi
from
Richmond, VA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
West End Dermatology Associates
mi
from
Richmond, VA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
TCR Medical Corporation
mi
from
San Diego, CA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
TCR Medical Corporation
mi
from
San Diego, CA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
UPMC Department of Dermatology
mi
from
Pittsburgh, PA
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
UPMC Department of Dermatology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
University of Connecticut Health Center (UConn Health)
mi
from
Farmington, CT
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
University of Connecticut Health Center (UConn Health)
mi
from
Farmington, CT
Click here to add this to my saved trials
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
MediSearch Clinical Trials
mi
from
Saint Joseph, MO
Study To Evaluate Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
A Phase 2b Randomized, Double‑Blind, Placebo-controlled, Parallel, Multicenter, Dose-ranging, Study To Evaluate The Efficacy And Safety Profile Of Pf-04965842 In Subjects With Moderate To Severe Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
MediSearch Clinical Trials
mi
from
Saint Joseph, MO
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Oceanside, CA
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Oceanside, CA
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Overland Park, KA
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Overland Park, KA
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Louisville, KY
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Omaha, NE
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Omaha, NE
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Rochester, NY
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Rochester, NY
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Duncansville, PA
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Duncansville, PA
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Johnston, RI
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Johnston, RI
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Nashville, TN
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Norfolk, VA
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Novartis Investigative Site
mi
from
Calgary,
Judging the Efficacy of Secukinumab in Patients With Psoriasis Using AutoiNjector: a Clinical Trial Evaluating Treatment Results (JUNCTURE)
A Randomized, Double-blind, Placebo Controlled, Multicenter Study of Subcutaneous Secukinumab in Autoinjectors to Demonstrate Efficacy After Twelve Weeks of Treatment, and to Assess the Safety, Tolerability, Usability and Long-term Efficacy in Subjects With Chronic Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Novartis Investigative Site
mi
from
Calgary,
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Pinnacle Research Group, LLC
mi
from
Anniston, AL
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Pinnacle Research Group, LLC
mi
from
Anniston, AL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Alliance Dermatology & MOHS Center, PC
mi
from
Phoenix, AZ
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Alliance Dermatology & MOHS Center, PC
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Southern California Dermatology, Inc.
mi
from
Santa Ana, CA
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Southern California Dermatology, Inc.
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Avail Clinical Research
mi
from
DeLand, FL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Jacksonville Center for Clinical Research
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Renstar Medical Research
mi
from
Ocala, FL
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Renstar Medical Research
mi
from
Ocala, FL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Advanced Clinical Research
mi
from
Boise, ID
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Advanced Clinical Research
mi
from
Boise, ID
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Menter Dermatology Research Institute
mi
from
Dallas, TX
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Menter Dermatology Research Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
New Horizon Research Center
mi
from
Miami, FL
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
New Horizon Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Medical Research South
mi
from
Charleston, SC
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Medical Research South
mi
from
Charleston, SC
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Dorothea
mi
from
Chomutov,
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Dorothea
mi
from
Chomutov,
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Clinical Research Atlanta
mi
from
Stockbridge, GA
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Clinical Research Atlanta
mi
from
Stockbridge, GA
Click here to add this to my saved trials
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated:  12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Parallel-Arm, Multiple-Dose, Active Comparator Trial
Status: Enrolling
Updated: 12/31/1969
Lynn Health Science Institute
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated:  12/31/1969
Dawes Fretzin Clinical Research
mi
from
Indianapolis, IN
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated: 12/31/1969
Dawes Fretzin Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated:  12/31/1969
PAREXEL-Phase 1 Baltimore Harbor Hospital Center
mi
from
Baltimore, MD
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated: 12/31/1969
PAREXEL-Phase 1 Baltimore Harbor Hospital Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated:  12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated: 12/31/1969
Altoona Center for Clinical Research
mi
from
Duncansville, PA
Click here to add this to my saved trials
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated:  12/31/1969
Parexel Early Phase Unit at Glendale
mi
from
Glendale, CA
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated: 12/31/1969
Parexel Early Phase Unit at Glendale
mi
from
Glendale, CA
Click here to add this to my saved trials
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
A Study of LY3041658 in Participants With Skin Diseases
A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3041658 in Patients With Skin Diseases
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Lycera Investigational Site
mi
from
East Windsor, NJ
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Lycera Investigational Site
mi
from
East Windsor, NJ
Click here to add this to my saved trials
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Lycera Investigational Site
mi
from
Carmel, IN
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Lycera Investigational Site
mi
from
Carmel, IN
Click here to add this to my saved trials
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Lycera Investigational Site
mi
from
Andover, MA
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Lycera Investigational Site
mi
from
Andover, MA
Click here to add this to my saved trials
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Lycera Investigational Site
mi
from
Fridley, MN
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Lycera Investigational Site
mi
from
Fridley, MN
Click here to add this to my saved trials
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Lycera Investigational Site
mi
from
High Point, NC
An Efficacy and Safety Study of LYC-30937-EC in Subjects With Moderate Chronic Plaque-type Psoriasis
A Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of LYC-30937-EC in Subjects With Moderate Chronic Plaque-Type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Lycera Investigational Site
mi
from
High Point, NC
Click here to add this to my saved trials